Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States

Rodrigo E. Mendes, David J. Farrell, Robert K. Flamm, George H. Talbot, Zrinka Ivezic-Schoenfeld, Susanne Paukner, Helio S. Sader
Rodrigo E. Mendes
aJMI Laboratories, North Liberty, Iowa, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Farrell
aJMI Laboratories, North Liberty, Iowa, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert K. Flamm
aJMI Laboratories, North Liberty, Iowa, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George H. Talbot
bTalbot Advisors LLC, Anna Maria, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zrinka Ivezic-Schoenfeld
cNabriva Therapeutics AG, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanne Paukner
cNabriva Therapeutics AG, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helio S. Sader
aJMI Laboratories, North Liberty, Iowa, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.00627-16
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Lefamulin was evaluated against various Streptococcus pneumoniae serotypes that were collected from adults with lower respiratory tract infections. Lefamulin exhibited MIC50 and MIC90 values of 0.12 and 0.25 μg/ml, respectively, against the entire collection (n = 822). Similar results were obtained for lefamulin against each of the most common serotypes as well as against multidrug-resistant isolates and strains that are nonsusceptible to ceftriaxone or erythromycin. These data support the clinical development of lefamulin for the treatment of community-acquired respiratory tract infections.

TEXT

Community-acquired respiratory tract infections (CARTIs) comprise a series of clinical syndromes, including community-acquired bacterial pneumonia (CABP), bacterial sinusitis, acute otitis media, and acute bacterial exacerbations of chronic bronchitis (1). CARTIs, especially CABP, are among the most frequent infections treated by physicians and represent a major international health problem (2). In addition, CABP represents the leading cause of hospitalizations in the United States and the main cause of morbidity and mortality among children and the elderly, with medical costs estimated at almost $1 billion and $17 billion annually in the United States, respectively (3, 4).

Lefamulin belongs to the pleuromutilin class of antimicrobial agents, which inhibits bacterial protein synthesis by selectively binding to the peptidyl transferase center of the bacterial ribosome and prevents the correct positioning of the 3′-CCA ends of tRNAs for peptide transfer (5–10). Lefamulin is the first pleuromutilin in development for intravenous and oral administration in humans (6), and it is currently in late-stage clinical development for the treatment of CABP and acute bacterial skin and skin structure infections (11–13). Lefamulin exhibits potent antibacterial activity against the most important respiratory and skin pathogens, including Streptococcus spp. and Staphylococcus spp., fastidious Gram-negative organisms, such as Haemophilus influenzae, and atypical respiratory pathogens, including Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila (14–16). In addition, in healthy human subjects, lefamulin (unbound protein) demonstrated extensive penetration and accumulation in pulmonary epithelial lining fluid, reaching a median total area under the concentration-time curve from 0 to 12 h (AUC0–12) of 5.78 μg · h/ml and a median maximum concentration of drug in serum (Cmax) of ∼0.7 μg/ml after a single 150-mg intravenous infusion over 1 h (17). This study evaluated the in vitro activity of lefamulin against specific serotypes of clinical isolates of Streptococcus pneumoniae.

A total of 822 S. pneumoniae isolates from 58 hospitals located in the nine United States Census regions as part of the SENTRY Antimicrobial Surveillance Program for 2010 were included. Isolates were recovered from lower respiratory tract specimens of adult patients aged ≥18 years and were submitted to a central monitoring laboratory (JMI Laboratories, North Liberty, IA, USA) for confirmation of bacterial identification, which was performed by biochemical algorithms and/or PCR assays as previously described (18). Serotypes were determined according to the sequence of cpsB in combination with multiplex PCR assays and the capsular swelling method (18). Isolates were tested for susceptibility by broth microdilution (19). Testing was performed using dry-form panels manufactured by Thermo Fisher Scientific (Cleveland, OH, USA) under appropriate quality assurance (20). Susceptibility interpretive criteria for comparator agents were those established by the Clinical and Laboratory Standards Institute and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (20, 21). An isolate was categorized as multidrug resistant (MDR) if it had elevated MIC results for three or more of the following drug classes (drug class probe): penicillins (penicillin, ≥4 μg/ml), cephalosporins (ceftriaxone, ≥2 μg/ml), macrolides (erythromycin, ≥0.5 μg/ml), tetracyclines (tetracycline HCl, ≥2 μg/ml), fluoroquinolones (levofloxacin, ≥4 μg/ml), lincosamides (clindamycin, ≥0.5 μg/ml), or folate pathway inhibitors (trimethoprim-sulfamethoxazole [TMP-SMX], ≥1/19 μg/ml).

In general, lefamulin exhibited a log-normal MIC distribution against the population of S. pneumoniae, with modal MIC, MIC50, and MIC90 results of 0.12, 0.12, and 0.25 μg/ml, respectively. In addition, all isolates were inhibited by lefamulin at ≤1 μg/ml (Table 1). Overall, MIC50 and MIC90 results for lefamulin remained at 0.12 and 0.25 μg/ml, respectively, when tested against (i) the most common serotypes, (ii) isolates displaying a nonsusceptible phenotype to ceftriaxone or erythromycin, and (iii) the MDR subset (Table 1). Slightly different MIC50 and MIC90 values were observed for lefamulin when it was tested against serotypes 3 and 11A/11D, showing lefamulin MIC50 and MIC90 results of 0.06 and 0.12 μg/ml and 0.25 and 0.5 μg/ml, respectively.

View this table:
  • View inline
  • View popup
TABLE 1

Lefamulin in vitro activity and cumulative MIC distributions against the overall population of S. pneumoniae selected serotypes and resistance subsets

The MIC values observed for lefamulin (MIC50 and MIC90, 0.12 and 0.25 μg/ml, respectively) against all isolates were similar to those obtained for imipenem (MIC50 and MIC90, ≤0.12 and 0.25 μg/ml; 100.0% susceptible) and were 2- to 4-fold lower than those for vancomycin (MIC50 and MIC90, 0.25 and 0.5 μg/ml, respectively; 100.0% susceptible), linezolid (MIC50 and MIC90, 1 and 1 μg/ml, respectively; 99.9% susceptible; data not shown), and levofloxacin (MIC50 and MIC90, 1 and 1 μg/ml, respectively; 98.9% susceptible) (Tables 2 and 3). Other comparators showed decreased antimicrobial activity against all S. pneumoniae isolates, including ceftriaxone (MIC50 and MIC90, ≤0.06 and 1 μg/ml, respectively; 92.6% susceptible), penicillin (MIC50 and MIC90, ≤0.03 and 4 μg/ml, respectively; 89.2% susceptible), clindamycin (MIC50 and MIC90, ≤0.25 and >1 μg/ml, respectively; 81.6% susceptible), erythromycin (MIC50 and MIC90, ≤0.06 and >8 μg/ml, respectively; 62.9% susceptible), tetracycline (MIC50 and MIC90, 0.5 and >8 μg/ml, respectively; 79.7% susceptible), and TMP-SMX (MIC50 and MIC90, ≤0.5 and 4 μg/ml, respectively; 71.3% susceptible) (Tables 2 and 3).

View this table:
  • View inline
  • View popup
TABLE 2

Antimicrobial susceptibility of the overall population of S. pneumoniae selected serotypes and resistance subsets based on CLSI breakpoints

View this table:
  • View inline
  • View popup
TABLE 3

In vitro activity of lefamulin and comparator agents against the overall population of S. pneumoniae selected serotypes and resistance subsets

Isolates were highly susceptible to penicillin and ceftriaxone except for serotypes 19A and 19F, for which susceptibility ranged from 38.2% to 75.0% (Table 2). When EUCAST breakpoints were applied, the proportions of intermediate and resistant isolates increased for the two compounds, especially for serotypes 19A, 35B, 6C/6D, 15A, and 19F (see Table S1 in the supplemental material). Clindamycin was also active against most serotypes, excluding 19A, 19F, and 15A/15F. In contrast, erythromycin had limited activity, with only serotypes 3 and 7F demonstrating high susceptibility rates (92.9% to 95.6% susceptible). Susceptibility rates obtained for tetracycline and TMP-SMX against most common serotypes varied, with the highest resistance rates among the serotypes 19F and 15A/15F for tetracycline and 19A, 6C/6D, and 19F for TMP-SMX; the proportion of intermediate isolates increased using EUCAST breakpoints.

A total of 21.9% of tested isolates displayed a MDR phenotype, and the majority (51.1%) of these S. pneumoniae isolates were serotype 19A or 19F, while 42.8% or 35.6% of MDR isolates are not covered by the 13-valent pneumococcal conjugate vaccine (PCV13) or the 23-valent pneumococcal polysaccharide vaccine (PPSV23), respectively (Table 1). Only lefamulin (MIC50 and MIC90, 0.12 and 0.25 μg/ml, respectively) (Tables 1 and 3), vancomycin (MIC50 and MIC90, 0.25 and 0.5 μg/ml, respectively), linezolid (MIC50 and MIC90, 1 and 1 μg/ml, respectively), and levofloxacin (MIC50 and MIC90, 1 and 1 μg/ml, respectively) demonstrated in vitro activity against MDR isolates (data not shown).

Recent reports have indicated a decrease in the prevalence of serotypes associated with PCV13 in children and adults (18, 22, 23), while other studies have documented an increase in non-PCV13 serotypes, including those with decreased antimicrobial susceptibility (24–27). Under these scenarios, additional alternatives for the treatment of CABP are needed. Potent and consistent lefamulin activity was observed regardless of serotype, including those not covered by PCV13 and those with a nonsusceptible phenotype to ceftriaxone or erythromycin or a MDR phenotype. The reasons for the small variation of lefamulin activity within serotypes (i.e., 3 and 11A/11D) need further investigation and may have been due to sample size.

Overall, when viewed in the context of the high pulmonary penetration observed in human subjects, these in vitro data support the continued clinical development of lefamulin for the treatment of patients with CABP, including those clinical cases caused by less-susceptible isolates.

ACKNOWLEDGMENTS

We thank the following staff members at JMI Laboratories (North Liberty, IA, USA) for technical support and/or assistance with manuscript preparation: M. Castanheira, L. Duncan, M. Janechek, R. Jones, M. Huband, J. Oberholser, P. Rhomberg, J. Ross, J. Schuchert, J. Streit, and L. Woosley.

JMI Laboratories, Inc. has received research and educational grants from 2014 to 2015 from Achaogen, Actavis, Actelion, Allergan, American Proficiency Institute (API), AmpliPhi, Anacor, Astellas, AstraZeneca, Basilea, Bayer, BD, Cardeas, Cellceutix, CEM-102 Pharmaceuticals, Cempra, Cerexa, Cidara, CorMedix, Cubist, Debiopharm, Dipexium, Dong Wha, Durata, Enteris, Exela, Forest Research Institute, Furiex, Genentech, GSK, Helperby, ICPD, Janssen, Lannett, Longitude, Medpace, Meiji Seika Kasha, Melinta, Merck, Motif, Nabriva, Novartis, Paratek, Pfizer, Pocared, PTC Therapeutics, Rempex, Roche, Salvat, Scynexis, Seachaid, Shionogi, Tetraphase, The Medicines Co., Theravance, Thermo Fisher, VenatoRx, Vertex, Wockhardt, and Zavante. Some JMI employees are advisors/consultants for Allergan, Astellas, Cubist, Pfizer, Cempra, and Theravance. With regard to speakers' bureaus and stock options, we have no conflicts of interest to declare.

FOOTNOTES

    • Received 18 March 2016.
    • Returned for modification 7 April 2016.
    • Accepted 1 May 2016.
    • Accepted manuscript posted online 9 May 2016.
  • Supplemental material for this article may be found at http://dx.doi.org/10.1128/AAC.00627-16.

  • Copyright © 2016, American Society for Microbiology. All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Stratton CW
    . 2005. An overview of community-acquired respiratory tract infections. Adv Stud Pharm 2:212–218.
    OpenUrl
  2. 2.↵
    1. Prina E,
    2. Ranzani OT,
    3. Torres A
    . 2015. Community-acquired pneumonia. Lancet 386:1097–1108. doi:10.1016/S0140-6736(15)60733-4.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Jain S,
    2. Williams DJ,
    3. Arnold SR,
    4. Ampofo K,
    5. Bramley AM,
    6. Reed C,
    7. Stockmann C,
    8. Anderson EJ,
    9. Grijalva CG,
    10. Self WH,
    11. Zhu Y,
    12. Patel A,
    13. Hymas W,
    14. Chappell JD,
    15. Kaufman RA,
    16. Kan JH,
    17. Dansie D,
    18. Lenny N,
    19. Hillyard DR,
    20. Haynes LM,
    21. Levine M,
    22. Lindstrom S,
    23. Winchell JM,
    24. Katz JM,
    25. Erdman D,
    26. Schneider E,
    27. Hicks LA,
    28. Wunderink RG,
    29. Edwards KM,
    30. Pavia AT,
    31. McCullers JA,
    32. Finelli L
    , CDC EPIC Study Team. 2015. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 372:835–845. doi:10.1056/NEJMoa1405870.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. File TM, Jr,
    2. Marrie TJ
    . 2010. Burden of community-acquired pneumonia in North American adults. Postgrad Med 122:130–141. doi:10.3810/pgm.2010.03.2130.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Shang R,
    2. Wang J,
    3. Guo W,
    4. Liang J
    . 2013. Efficient antibacterial agents: a review of the synthesis, biological evaluation and mechanism of pleuromutilin derivatives. Curr Top Med Chem 13:3013–3025. doi:10.2174/15680266113136660217.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Novak R
    . 2011. Are pleuromutilin antibiotics finally fit for human use? Ann N Y Acad Sci 1241:71–81. doi:10.1111/j.1749-6632.2011.06219.x.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Eyal Z,
    2. Matzov D,
    3. Krupkin M,
    4. Wekselman I,
    5. Paukner S,
    6. Zimmerman E,
    7. Rozenberg H,
    8. Bashan A,
    9. Yonath A
    . 2015. Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus. Proc Natl Acad Sci U S A 112:E5805–E5814. doi:10.1073/pnas.1517952112.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Schlunzen F,
    2. Pyetan E,
    3. Fucini P,
    4. Yonath A,
    5. Harms JM
    . 2004. Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol Microbiol 54:1287–1294. doi:10.1111/j.1365-2958.2004.04346.x.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Davidovich C,
    2. Bashan A,
    3. Auerbach-Nevo T,
    4. Yaggie RD,
    5. Gontarek RR,
    6. Yonath A
    . 2007. Induced-fit tightens pleuromutilins binding to ribosomes and remote interactions enable their selectivity. Proc Natl Acad Sci U S A 104:4291–4296. doi:10.1073/pnas.0700041104.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Long KS,
    2. Hansen LH,
    3. Jakobsen L,
    4. Vester B
    . 2006. Interaction of pleuromutilin derivatives with the ribosomal peptidyl transferase center. Antimicrob Agents Chemother 50:1458–1462. doi:10.1128/AAC.50.4.1458-1462.2006.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Rubino CM,
    2. Xue B,
    3. Bhavnani SM,
    4. Prince WT,
    5. Ivezic-Schoenfeld Z,
    6. Wicha WW,
    7. Ambrose PG
    . 2015. Population pharmacokinetic analyses for BC-3781 using phase 2 data from patients with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 59:282–288. doi:10.1128/AAC.02033-13.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Prince WT,
    2. Ivezic-Schoenfeld Z,
    3. Lell C,
    4. Tack KJ,
    5. Novak R,
    6. Obermayr F,
    7. Talbot GH
    . 2013. Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 57:2087–2094. doi:10.1128/AAC.02106-12.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Bhavnani SM,
    2. Ambrose PG,
    3. Wicha WW,
    4. Ivezic-Schoenfeld Z,
    5. Prince WT,
    6. Rubino CM
    . 2015. Pharmacokinetic-pharmacodynamic (PK-PD) target attainment (TA) analyses supporting lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia (CABP), abstr 793. ID Week, San Diego, CA, 7 to 11 October 2015.
  14. 14.↵
    1. Sader HS,
    2. Biedenbach DJ,
    3. Paukner S,
    4. Ivezic-Schoenfeld Z,
    5. Jones RN
    . 2012. Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against gram-positive organisms commonly associated with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 56:1619–1623. doi:10.1128/AAC.05789-11.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Sader HS,
    2. Paukner S,
    3. Ivezic-Schoenfeld Z,
    4. Biedenbach DJ,
    5. Schmitz FJ,
    6. Jones RN
    . 2012. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs). J Antimicrob Chemother 67:1170–1175. doi:10.1093/jac/dks001.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Paukner S,
    2. Sader HS,
    3. Ivezic-Schoenfeld Z,
    4. Jones RN
    . 2013. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrob Agents Chemother 57:4489–4495. doi:10.1128/AAC.00358-13.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Zeitlinger M,
    2. Schwameis R,
    3. Burian A,
    4. Burian B,
    5. Matzneller P,
    6. Muller M,
    7. Wicha WW,
    8. Strickmann DB,
    9. Prince W
    . 2016. Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid. J Antimicrob Chemother 71:1022–1026. doi:10.1093/jac/dkv442.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Mendes RE,
    2. Hollingsworth RC,
    3. Costello A,
    4. Jones RN,
    5. Isturiz RE,
    6. Hewlett D, Jr,
    7. Farrell DJ
    . 2015. Noninvasive Streptococcus pneumoniae serotypes recovered from hospitalized adult patients in the United States in 2009 to 2012. Antimicrob Agents Chemother 59:5595–5601. doi:10.1128/AAC.00182-15.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing; 25th informational supplement. CLSI M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA.
  20. 20.↵
    Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing; 26th informational supplement. CLSI M100-S26. Clinical and Laboratory Standards Institute, Wayne, PA.
  21. 21.↵
    EUCAST. 2016. Breakpoint tables for interpretation of MICs and zone diameters. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_6.0_Breakpoint_table.pdf.
  22. 22.↵
    1. Moore MR,
    2. Link-Gelles R,
    3. Schaffner W,
    4. Lynfield R,
    5. Lexau C,
    6. Bennett NM,
    7. Petit S,
    8. Zansky SM,
    9. Harrison LH,
    10. Reingold A,
    11. Miller L,
    12. Scherzinger K,
    13. Thomas A,
    14. Farley MM,
    15. Zell ER,
    16. Taylor TH, Jr,
    17. Pondo T,
    18. Rodgers L,
    19. McGee L,
    20. Beall B,
    21. Jorgensen JH,
    22. Whitney CG
    . 2015. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 15:301–309. doi:10.1016/S1473-3099(14)71081-3.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Desai AP,
    2. Sharma D,
    3. Crispell EK,
    4. Baughman W,
    5. Thomas S,
    6. Tunali A,
    7. Sherwood L,
    8. Zmitrovich A,
    9. Jerris R,
    10. Satola SW,
    11. Beall B,
    12. Moore MR,
    13. Jain S,
    14. Farley MM
    . 2015. Decline in pneumococcal nasopharyngeal carriage of vaccine serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in children in Atlanta, Georgia. Pediatr Infect Dis J 34:1168–1174. doi:10.1097/INF.0000000000000849.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Mendes RE,
    2. Biek D,
    3. Critchley IA,
    4. Farrell DJ,
    5. Sader HS,
    6. Jones RN
    . 2014. Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agents. Antimicrob Agents Chemother 58:4923–4927. doi:10.1128/AAC.02976-14.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Richter SS,
    2. Diekema DJ,
    3. Heilmann KP,
    4. Dohrn CL,
    5. Riahi F,
    6. Doern GV
    . 2014. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother 58:6484–6489. doi:10.1128/AAC.03344-14.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Richter SS,
    2. Heilmann KP,
    3. Dohrn CL,
    4. Riahi F,
    5. Diekema DJ,
    6. Doern GV
    . 2013. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011. Emerg Infect Dis 19:1074–1083. doi:10.3201/eid1907.121830.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Link-Gelles R,
    2. Thomas A,
    3. Lynfield R,
    4. Petit S,
    5. Schaffner W,
    6. Harrison L,
    7. Farley MM,
    8. Aragon D,
    9. Nicols M,
    10. Kirley PD,
    11. Zansky S,
    12. Jorgensen J,
    13. Juni BA,
    14. Jackson D,
    15. Moore MR,
    16. Lipsitch M
    . 2013. Geographic and temporal trends in antimicrobial nonsusceptibility in Streptococcus pneumoniae in the post-vaccine era in the United States. J Infect Dis 208:1266–1273. doi:10.1093/infdis/jit315.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Download PDF
Citation Tools
In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States
Rodrigo E. Mendes, David J. Farrell, Robert K. Flamm, George H. Talbot, Zrinka Ivezic-Schoenfeld, Susanne Paukner, Helio S. Sader
Antimicrobial Agents and Chemotherapy Jun 2016, 60 (7) 4407-4411; DOI: 10.1128/AAC.00627-16

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States
Rodrigo E. Mendes, David J. Farrell, Robert K. Flamm, George H. Talbot, Zrinka Ivezic-Schoenfeld, Susanne Paukner, Helio S. Sader
Antimicrobial Agents and Chemotherapy Jun 2016, 60 (7) 4407-4411; DOI: 10.1128/AAC.00627-16
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596